Roivant Sciences Ltd. (NASDAQ: ROIV - Get Free Report) Director Melissa Epperly sold 4,938 shares of

Analysts initiated coverage: Buy ratings for MNOV ($6), IBIO ($7), ROIV ($51), and PAY ($42); FHN ra

Stifel analyst Alex Thompson initiates coverage on Roivant Sciences (NASDAQ:ROIV) with a Buy rati

TD Cowen analyst Yaron Werber maintains Roivant Sciences (NASDAQ:ROIV) with a Buy and raises the

Guggenheim analyst Yatin Suneja maintains Roivant Sciences (NASDAQ:ROIV) with a Buy and raises th

HC Wainwright & Co. analyst Douglas Tsao maintains Roivant Sciences (NASDAQ:ROIV) with a Buy

Crude near $98 pushes the 10-year Treasury yield above 4.8% for the first time since 2023, hammering

Gainers Indaptus Therapeutics (NASDAQ:INDP) stock increased by 46.7% to $1.79 during Tuesday's

U.S. stocks fell Tuesday as health care lagged, while energy gained. ABM beat estimates; oil rose, a

Jefferies analyst Dennis Ding maintains Roivant Sciences (NASDAQ:ROIV) with a Buy and raises the

U.S. stocks fell Tuesday, but Roivant surged 16% on positive PH-ILD trial data. Pharvaris, Solaris,

Roivant announced positive Phase 2 trial results for mosliciguat, demonstrating improved walk distan

Gainers iSpecimen (NASDAQ:ISPC) stock increased by 22.7% to $1.89 during Tuesday's pre-market s

"PH-ILD remains one of the most challenging forms of pulmonary hypertension to treat, given the

FDA approves Roivant's LISRAYA for adult dermatomyositis, offering a once-daily targeted therapy

HC Wainwright & Co. analyst Douglas Tsao reiterates Roivant Sciences (NASDAQ:ROIV) with a Buy

Arbutus Biopharma (ABUS) stock rises after announcing a $230M stock buyback via a modified Dutch auc